 POSITRON EMISSION TOMOGRAPHY USING FLUDEOXYGLUCOSE F 18 IN PREDICTING RESPONSE TO TREATMENT IN PATIENTS WHO ARE RECEIVING RITUXIMAB AND COMBINATION CHEMOTHERAPY FOR NEWLY DIAGNOSED NON-HODGKINS LYMPHOMA: 